Patents-Review.com
ClassID:

116075 ⎘

C12Y207/11022 - CPC Classification

Classification description:

Transferases transferring phosphorus-containing groups (2.7); Protein-serine/threonine kinases (2.7.11) Cyclin-dependent kinase (2.7.11.22)

Recent Application in this class:
#1
20260103719
2026-04-16

POLYNUCLEOTIDE, PROTEIN, BIOLOGICAL MATERIAL, AND USE THEREOF IN IMPROVING QUALITY OF PLANT FRUIT

 #2
20250179499
2025-06-05

USE OF CDK16 AS TARGET IN PREPARATION OF MEDICINE FOR TREATING TRIPLE-NEGATIVE BREAST CANCER

 #3
20250093362
2025-03-20

HIGH-THROUGHPUT ENGINEERING OF MOLECULAR GLUES

 #4
20250043305
2025-02-06

GENETIC CONSTRUCT FOR TRACKING AND/OR ABLATING QUIESCENT CELLS

 #5
20240415974
2024-12-19

PROTEIN-BASED CONJUGATION CARRIERS

 #6
20230407274
2023-12-21

Compositions and methods involving engineered P27

 #7
20230338528
2023-10-26

SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES

 #8
20230310546
2023-10-05

METHODS FOR INDUCING CELL DIVISION OF POSTMITOTIC CELLS

 #9
20230192863
2023-06-22

METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY

 #10
20220251550
2022-08-11

METHODS FOR EXTENDING THE REPLICATIVE CAPACITY OF SOMATIC CELLS DURING AN EX VIVO CULTIVATION PROCESS

 #11
20220169735
2022-06-02

Methods of sensitizing cancer to immunotherapy

 #12
20220112494
2022-04-14

IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA

 #13
20210268072
2021-09-02

TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof

 #14
20210172026
2021-06-10

Compositions and methods for predicting response and resistance to CDK4/6 inhibition

 #15
20210002619
2021-01-07

Compositions and methods involving engineered p27

 #16
20200299654
2020-09-24

CDKL5 EXPRESSION VARIANTS AND CDKL5 FUSION PROTEINS

 #17
20200199549
2020-06-25

TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

 #18
20200165691
2020-05-28

Methods for inducing cell division of postmitotic cells

 #19
20200054640
2020-02-20

METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER

 #20
20190316138
2019-10-17

Oligonucleotide compositions with enhanced efficiency

 #21
20190194330
2019-06-27

Methods of sensitizing cancer to immunotherapy

 #22
20190192518
2019-06-27

Compositions and methods for treating and preventing metabolic disorders

 #23
20190085328
2019-03-21

In vivo gene silencing by chemically modified and stable siRNA

 #24
20190032146
2019-01-31

Compositions and methods for predicting response and resistance to CDK4/6 inhibition

 #25
20190024079
2019-01-24

METHODS FOR EXTENDING THE REPLICATIVE CAPACITY OF SOMATIC CELLS DURING AN EX VIVO CULTIVATION PROCESS

 #26
20190017051
2019-01-17

Oligonucleotide compositions with enhanced efficiency

 #27
20190002880
2019-01-03

DOUBLE-STRANDED OLIGONUCLEOTIDES

 #28
20180334702
2018-11-22

Cyclin-dependent kinase substrate

 #29
20180327725
2018-11-15

TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

 #30
20180266014
2018-09-20

Fusion protein crystal comprising a moiety

 #31
20180112282
2018-04-26

Methods for inducing cell division of postmitotic cells

 #32
20180110777
2018-04-26

METHOD FOR REGULATION OF TELOMERE LENGTH

 #33
20180087056
2018-03-29

Oligonucleotide compositions with enhanced efficiency

 #34
20180064746
2018-03-08

Assay for telomere length regulators

 #35
20170321219
2017-11-09

Oligonucleotide compositions with enhanced efficiency

 #36
20170173021
2017-06-22

Method and kits for identifying of CDK9 inhibitors for the treatment of cancer

 #37
20170044611
2017-02-16

Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes

 #38
20160289650
2016-10-06

FLUORESCENT PROTEIN BIOSENSORS TO PROBE THE CONFORMATIONAL ACTIVATION OF CDK/CYCLIN KINASES

 #39
20160194617
2016-07-07

TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

 #40
20150299703
2015-10-22

In vivo gene silencing by chemically modified and stable siRNA

 #41
20150247134
2015-09-03

TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

 #42
20150057333
2015-02-26

Double-stranded oligonucleotides

 #43
20140030809
2014-01-30

Method for producing epithelial stem cells

 #44
20130303586
2013-11-14

Oligonucleotide compositions with enhanced efficiency

 #45
20130174286
2013-07-04

In vivo gene silencing by chemically modified and stable siRNA

 #46
20130045520
2013-02-21

Double-stranded oligonucleotides

 #47
20120156180
2012-06-21

COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES

 #48
20120107897
2012-05-03

DOUBLE-STRANDED OLIGONUCLEOTIDES

 #49
20120095074
2012-04-19

Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes

 #50
20110286997
2011-11-24

Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes

 #51
20110086425
2011-04-14

DELIVERY OF siRNAs

 #52
20100298408
2010-11-25

Oligonucleotide Compositions with Enhanced Efficiency

 #53
20100143440
2010-06-10

UL97 INHIBITORS FOR TREATMENT OF PROLIFERATIVE DISORDERS

 #54
20100136695
2010-06-03

DOUBLE-STRANDED OLIGONUCLEOTIDES

 #55
20100113560
2010-05-06

Methods for treating hematopoietic malignancies

 #56
20090023216
2009-01-22

Double-Stranded Oligonucleotides

 #57
20060009409
2006-01-12

Double-stranded oligonucleotides

 #58
20050020521
2005-01-27

In vivo gene silencing by chemically modified and stable siRNA